RxDoctor Payments Data

Dixon Xu, DPM

Foot & Ankle Surgery · Chula Vista, CANPI 1598296600

Payments from drug & device makers

$3,712in general payments, 2019–2025

Across 91 payments — averaging $40.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medline Industries LP$713
  • Paragon 28, Inc.$630
  • Stryker$401
  • Smith+Nephew$214
  • AbbVie$201
  • Integra Lifesciences Corporation$185
  • plus $1K from 26 others

What the payments were for

  • Travel & lodging$1,27134%
  • Food & beverage$2,44166%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,712 in reported general payments places this provider in the 65th percentile of 1,126 foot & ankle surgery providers in California.

See all foot & ankle surgery providers in California

Medicare billing

Part B allowed, 2024
$113,490
Medicare patients
383
Services billed
1,650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.19$5,573
Clotrimazole154$5,119
Ketoconazole119$4,225
Diclofenac Sodium72$1,444
Ammonium Lactate90$1,371
Ciclopirox15$844
Terbinafine Hcl35$714
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav53$674
Clindamycin Phosphate20$661
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip17$269
Lidocaine-PrilocaineLidocaine/Prilocaine20$267
Doxycycline Monohydrate20$233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$214$5,57319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,126 foot & ankle surgery providers in California.

Other foot & ankle surgery in Chula Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →